About Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (M
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Company type
- Public Company
- Company profile name
- Monte Rosa Therapeutics
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.
Company locations
321 Harrison Ave, Suite 900, Boston, Massachusetts 02118, US
Klybeckstrasse 191, WKL 136.3, Basel, 4057, CH
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
On LinkedIn
- Followers
- 33,454
- People linked to this company
- 213
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.